Format

Send to

Choose Destination
J Drugs Dermatol. 2006 May;5(5):436-40.

Poly-L-lactic acid: an overview.

Author information

1
Sanofi-Aventis, Berwyn, PA 19312, USA. Pahala.Simamora@sanofi-aventis.com

Abstract

In August 2004, the US Food and Drug Administration approved a poly-L-lactic acid (PLLA)-based injectable medical device for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. As a result, the properties of the PLLA microparticles have received considerable interest from the medical community. Polylactides have a long-standing history of safe use in medical applications, such as pins, plates, screws, intra-bone and soft-tissue implants, and as vectors for sustained release of bioactive compounds. The L-isomer of polylactic acid is a biodegradable, biocompatible, biologically inert, synthetic polymer. Putatively, PLLA microparticles initiate neocollagenesis as a result of a normal foreign-body reaction to their presence. The build-up of collagen over time creates volume at the site of injection, while the PLLA microparticles are metabolized to carbon dioxide and water and expelled through the respiratory system.

PMID:
16703779
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center